Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer is a research paper published in Annals of Oncology (2020). On theSindex it has a DataRank of 0.759. It has been cited 157 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.759
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: P50 CA168504
NIH
Grant: UM1 CA186709
Yale Cancer Center
Grant: 1UM1CA86689-05
Department of Defense
Grant: W81XWH-13-1-0032
AACR Landon Foundation
Grant: 13-60-27-WAGL
National Institutes of Health
Grant: 5P50CA168504-03
Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer
National Institutes of Health
Grant: 5UM1CA186709-09
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)
National Institutes of Health
Grant: 3P30CA006516-41S6
CANCER CENTER SUPPORT GRANT
National Institutes of Health
Grant: 5UM1CA186709-05
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis
Fields of Study
Keywords
Sustainable Development Goals